2658-6533Research Results in Biomedicine2658-653310.18413/2658-6533-2025-11-2-0-63771Pharmacology<strong>Metabolic and functional effects of complex therapy of renal and cardiovascular pathology with sodium-glucose cotransporter type 2 inhibitors in patients with diabetes mellitus and Covid-19 (review)</strong><br /> &nbsp;<strong>Metabolic and functional effects of complex therapy of renal and cardiovascular pathology with sodium-glucose cotransporter type 2 inhibitors in patients with diabetes mellitus and Covid-19 (review)</strong><br /> &nbsp;DzugkoevSergey G.DzugkoevSergey G.biohimik-bog@mail.ruDzugkoevaFira S.DzugkoevaFira S.patbiochem@mail.ruKhubulovaAnna E.KhubulovaAnna E.kvizia@mail.ruMargievaOlga I.MargievaOlga I.margievaolga@mail.ru202511200

Background: Studying the mechanisms of development of chronic kidney pathology and concomitant disorders of the cardiovascular system in patients with type 2 diabetes mellitus (DM2) and its combination with Covid-19 remains an urgent problem. Modern methods of treating patients with diabetes recommend the use of a new class of drugs &ndash; inhibitors of the activity of sodium-glucose cotransporter-2, as well as those stimulating insulin secretion: glucagon-like peptide agonists, dipeptidyl pentidase-4 inhibitors. The aim of the study: Analysis of literature data on the mechanisms of action of sodium glucose cotransporter inhibitors in the treatment of chronic renal and cardiovascular pathology in patients with DM and Covid-19. Materials and methods: The methodological approaches used in the review to achieve this goal are based on the study of abstract databases: PubMed, Google scholar, E-library literature sources of the last 10 years (more than 135 sources), of which the review included data from 58 articles: 24 original articles, 18 reviews, 6 meta-analyses, 1 letter to the editor, 1 randomized trial, 6 retrospective cohort studies, 2 European and American Association position statements. Results: The mechanisms of action of type 2 SGLT inhibitors are considered in the light of reno- and cardioprotection. The ability of NGLT-2 to have a positive effect on the processes of proximal reabsorption of glucose and sodium, as well as on the glomerular filtration rate (GFR) was revealed. An analysis of the mechanisms of the relationship between diabetes and Covid-19 was carried out. The antioxidant capacity of these drugs was established due to the suppression of LPO activity in the mitochondria of the cells of the proximal tubules of the kidneys. The hypoglycemic effect of NGLT-2, improvement of glycemic control, reduction of body weight and blood pressure has been established. In the group of patients with type 2 diabetes, taking empagliflazine caused a suppression of the incidence of increases in creatinine by 46%, and the need for renal replacement therapy by 55% compared with placebo. Follow-up of patients showed long-term stabilization of renal function, which was reflected in the maintenance of GFR levels and a reduction in deaths by 40%. The mechanisms of action of other drugs were analyzed: metformin and glucocorticoids in diabetes and Covid-19. Conclusion: Epidemiological studies have revealed that diabetes is a risk factor for the development of pathology of the cardiorenal system in combination with Covid-19. The inclusion of SGLT-2 inhibitors in antidiabetic therapy can increase the effectiveness of treatment and their ability to provide nephroprotective and cardioprotective effects

Background: Studying the mechanisms of development of chronic kidney pathology and concomitant disorders of the cardiovascular system in patients with type 2 diabetes mellitus (DM2) and its combination with Covid-19 remains an urgent problem. Modern methods of treating patients with diabetes recommend the use of a new class of drugs &ndash; inhibitors of the activity of sodium-glucose cotransporter-2, as well as those stimulating insulin secretion: glucagon-like peptide agonists, dipeptidyl pentidase-4 inhibitors. The aim of the study: Analysis of literature data on the mechanisms of action of sodium glucose cotransporter inhibitors in the treatment of chronic renal and cardiovascular pathology in patients with DM and Covid-19. Materials and methods: The methodological approaches used in the review to achieve this goal are based on the study of abstract databases: PubMed, Google scholar, E-library literature sources of the last 10 years (more than 135 sources), of which the review included data from 58 articles: 24 original articles, 18 reviews, 6 meta-analyses, 1 letter to the editor, 1 randomized trial, 6 retrospective cohort studies, 2 European and American Association position statements. Results: The mechanisms of action of type 2 SGLT inhibitors are considered in the light of reno- and cardioprotection. The ability of NGLT-2 to have a positive effect on the processes of proximal reabsorption of glucose and sodium, as well as on the glomerular filtration rate (GFR) was revealed. An analysis of the mechanisms of the relationship between diabetes and Covid-19 was carried out. The antioxidant capacity of these drugs was established due to the suppression of LPO activity in the mitochondria of the cells of the proximal tubules of the kidneys. The hypoglycemic effect of NGLT-2, improvement of glycemic control, reduction of body weight and blood pressure has been established. In the group of patients with type 2 diabetes, taking empagliflazine caused a suppression of the incidence of increases in creatinine by 46%, and the need for renal replacement therapy by 55% compared with placebo. Follow-up of patients showed long-term stabilization of renal function, which was reflected in the maintenance of GFR levels and a reduction in deaths by 40%. The mechanisms of action of other drugs were analyzed: metformin and glucocorticoids in diabetes and Covid-19. Conclusion: Epidemiological studies have revealed that diabetes is a risk factor for the development of pathology of the cardiorenal system in combination with Covid-19. The inclusion of SGLT-2 inhibitors in antidiabetic therapy can increase the effectiveness of treatment and their ability to provide nephroprotective and cardioprotective effects

diabetes mellitussodium glucose cotransporter type 2 inhibitorsnephropathycardiovascular insufficiencyCovid-19diabetes mellitussodium glucose cotransporter type 2 inhibitorsnephropathycardiovascular insufficiencyCovid-19Список литературыKolegova II, Chernyavina AI, Koziolova NA. Characteristics of the course of chronic heart failure and the state of target organs in patients with cardiorenal syndrome. Russian Journal of Cardiology. 2018;1:21-26. Russian. DOI: https://doi.org/10.15829/1560-4071-2018-1-21-26Montiel V, Lobysheva I, G&eacute;rard L, et al. Oxidative stress-induced endothelial dysfunction and decreased vascular nitric oxide in COVID-19 patients. eBioMedicine. 2022;77:103893. DOI: https://doi.org/10.1016/j.ebiom.2022.103893Zverev YaF, Rykunova Aya. Glomerular filtration barrier disorders as a cause of proteinuria in nephrotic syndrome. Nephrology (Saint-Petersburg). 2019;23(4):96-111. Russian. DOI: https://doi.org/10.24884/1561-6274-2019-23-4-96-111Rotermund C, Machetanz G, Fitzgerald JC. The Therapeutic Potential of Metformin in Neurodegenerative Diseases. Frontiers in Endocrinology. 2018;9:400. DOI: https://doi.org/10.3389/fendo.2018.00400Tokubuchi I, Tajiri Y, Iwata S, et al. Beneficial effects of metformin on energy metabolism and visceral fat volume through a possible mechanism of fatty acid oxidation in human subjects and rats. PLoS ONE. 2017;12(2):e0171293. DOI: https://doi.org/10.1371/journal.pone.0171293van Stee MF, de Graaf AA, Groen AK. Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy. Cardiovascular Diabetology. 2018;17(1):94. DOI: https://doi.org/10.1186/s12933-018-0738-4Kurmanbekova BT, Noruzbaeva AM. Cardiovascular effects of metformin. Rational Pharmacotherapy in Cardiology. 2022;18(1):97-102. Russian. DOI: https://doi.org/10.20996/1819-6446-2022-02-12Batyushin MM. The use of sodium-glucose cotransporter type 2 inhibitors in chronic heart failure and chronic kidney disease. The role of empagliflozin. Russian Journal of Cardiology. 2021;26(S1):4349. Russian. DOI: https://doi.org/10.15829/1560-4071-2021-4349Nespoux J, Vallon V. Renal effects of SGLT2 inhibitors: an update. Current Opinion in Nephrology and Hypertension. 2020;29(2):190-198. DOI: https://doi.org/10.1097/MNH.0000000000000584Sabirov IS, Murkamilov IT, Fomin VV, et al. SGLT-2 inhibitors in chronic kidney disease: state of the art. Clinical Pharmacology and Therapy. 2022;31(3):53-58. Russian. DOI: https://doi.org/10.32756/0869-5490-2022-3-53-58Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017;60(2):215-225. https://doi.org/10.1007/s00125-016-4157-3Wilcox CS. Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors. Hypertension. 2020;75(4):894-901. DOI: https://doi.org/10.1161/hypertensionaha.119.11684Demidova TYu, Alekseeva YaG. Metabolic and hemodynamic effects of a new sodium-glucose cotransporter type 2 inhibitor ipragliflozin in the treatment of type 2 diabetes mellitus. Atmosphere. Cardiology News. 2020;1:38-47. Russian. DOI: https://doi.org/10.24411/2076-4189-2020-12203Plakhotnyaya VM, Martynova EY, Poteshkin YuE. Sodium-glucose cotransporter 1: a role in the pathogenesis of type 2 diabetes mellitus and other diseases and a potential therapeutic target. Effektivnaya farmakoterapiya. 2022;18(2):42-54. Russian. DOI: https://doi.org/10.33978/2307-3586-2022-18-2-42-54Dos Santos SD, Polidoro JZ, Borges-J&uacute;nior FA, et al. Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective. American Journal of Physiology - Cell Physiology. 2020;318(2):328-36. DOI: https://doi.org/10.1152/ajpcell.00275.2019Martynov SA, Shamkhalova MSh. The role of sodium-glucose cotransporter 2 inhibitors in slowing the progression of renal failure in patients with type 2 diabetes mellitus. Effektivnaya farmakoterapiya. 2021;17(5):16-23. Russian. DOI: https://doi.org/10.33978/2307-3586-2021-17-5-16-23Kidokoro K, Cherney DZI, Bozovic A, et al. Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging. Circulation. 2019;140(4):303-15. DOI: https://doi.org/10.1161/CIRCULATIONAHA.118.037418Bae JH, Park EG, Kim S, et al. Effects of sodium-glucose cotransporter 2 inhibitors on renal outcomes in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Scientific Reports. 2019;9(1):13009. DOI: https://doi.org/10.1038/s41598-019-49525-yMulder S, Heerspink HJL, Darshi M, et al. Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes. Diabetes, Obesity and Metabolism. 2019;21(1):2422-2428. DOI: https://doi.org/10.1111/dom.13823Lee YH, Kim SH, Kang JM, et al. Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy. American Journal of Physiology - Renal Physiology. 2019;317:767-780. DOI: https://doi.org/10.1152/ajprenal.00565.2018Lebedev DA, Likhonosov NP, Tuchina TP, et al. Assessment of SGLT2 inhibitors on kidney morphology and albumin excretion in rats with experimental diabetes mellitus type 1. Problems of Endocrinology. 2016;62(5):12-13. Russian. DOI: https://doi.org/10.14341/probl201662512-13Han JH, Oh TJ, Lee G, et al. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE&ndash;/&ndash; mice fed a Western diet. Diabetologia. 2017;60(2):364-376. DOI: https://doi.org/10.1007/s00125-016-4158-2Layton AT, Vallon V. SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism. American Journal of Physiology - Renal Physiology. 2018;314(5):969-984. DOI: https://doi.org/10.1152/ajprenal.00551.2017Sato T, Aizawa Y, Yuasa S, et al. The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovascular Diabetology. 2018;17(1):6. DOI: https://doi.org/10.1186/s12933-017-0658-8Iacobellis G, Barbaro G. Epicardial adipose tissue feeding and overfeeding the heart. Nutrition. 2019;59:1-6. DOI: https://doi.org/10.1016/j.nut.2018.07.002Bailey CJ. Uric acid and the cardio-renal effects of SGLT2 inhibitors. Diabetes, Obesity and Metabolism. 2019;21(6):1291-1298. DOI: https://doi.org/10.1111/dom.13670Zhao Y, Xu L, Tian D, et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials. Diabetes Obesity and Metabolism. 2018;20(2):458-462. DOI: https://doi.org/10.1111/dom.13101Baartscheer A, Schumacher CA, W&uuml;st RC, et al. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. Diabetologia. 2017;60(3):568-573. DOI: https://doi.org/10.1007/s00125-016-4134-xCowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nature Reviews Cardiology. 2020;17(12):761-772. DOI: https://doi.org/10.1038/s41569-020-0406-8Kimura Y, Kuno A, Tanno M, et al. Canagliflozin, a sodium-glucose cotransporter 2 inhibitor, normalizes renal susceptibility to type 1 cardiorenal syndrome through reduction of renal oxidative stress in diabetic rats. Journal of Diabetes Investigation. 2019;10(4):933-946. DOI: https://doi.org/10.1111/jdi.13009Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia &ndash; A systematic review, meta-analysis, and meta-regression. Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 2020;14(4):395-403. DOI: https://doi.org/10.1016/j.dsx.2020.04.018Wu J, Li W, Shi X, et al. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID‐19). Journal of Internal Medicine. 2020;288(1):128-138. DOI: https://doi.org/10.1111/joim.13063Mokrysheva NG, Shestakova MV, Vikulova OK, et al. Analysis of risk factors for COVID-19-related fatal outcome in 337991 patients with type 1 and type 2 diabetes mellitus in 2020&ndash;2022 years: Russian nationwide retrospective study. Diabetes mellitus. 2022;25(5):404-417. Russian. DOI: https://doi.org/10.14341/DM12954Shestakova MV, Vikulova OK, Elfimova AR, et al. Risk factors for COVID-19 case fatality rate in people with type 1 and type 2 diabetes mellitus: A nationwide retrospective cohort study of 235,248 patients in the Russian Federation. Frontiers in Endocrinology. 2022;13:909874. DOI: https://doi.org/10.3389/fendo.2022.909874Shestakova MV, Vikulova OK, Isakov MА, et al. Diabetes and COVID-19: analysis of the clinical outcomes according to the data of the russian diabetes registry. Problems of Endocrinology. 2020;66(1):35-46. Russian. DOI: https://doi.org/10.14341/probl12458Rawshani A, Kj&ouml;lhede EA, Rawshani A, et al. Severe COVID-19 in people with type 1 and type 2 diabetes in Sweden: A nationwide retrospective cohort study. The Lancet Regional Health - Europe. 2021;4:100105. DOI: https://doi.org/10.1016/j.lanepe.2021.100105Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. The Lancet Diabetes and Endocrinology. 2020;8(10):813-822. DOI: https://doi.org/10.1016/S2213-8587(20)30272-2Holman N, Knighton P, Kar P, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. The Lancet Diabetes and Endocrinology. 2020;8(10):823-833. DOI: https://doi.org/10.1016/S2213-8587(20)30271-0Ando W, Horii T, Uematsu T, et al. Impact of overlapping risks of type 2 diabetes and obesity on coronavirus disease severity in the United States. Scientific Reports. 2021;11(1):17968. DOI: https://doi.org/10.1038/s41598-021-96720-xKhunti K, Knighton P, Zaccardi F, et al. Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people тwith type 2 diabetes: a nationwide observational study in England. The Lancet Diabetes and Endocrinology. 2021;9(5):293-303. DOI: https://doi.org/10.1016/S2213-8587(21)00050-4Mali SN, Thorat BR, Chopade AR. A Viewpoint on Angiotensin-Converting Enzyme 2, Anti-Hypertensives and Coronavirus Disease 2019 (COVID-19). Infectious Disorders - Drug Targets. 2021;21(3):311-313. DOI: https://doi.org/10.2174/1871526520666200511005546Zhu L, She Z-G, Cheng X, et al. Association of blood glucose control and outcomes in patients with COVID-19 and Pre-existing type 2 diabetes. Cell Metabolism. 2020;31(6):1068-1077. DOI: https://doi.org/10.1016/j.cmet.2020.04.021Kastora S, Patel M, Carter B, et al. Impact of diabetes on COVID‐19 mortality and hospital outcomes from a global perspective: An umbrella systematic review and meta‐analysis. Endocrinology, Diabetes and Metabolism. 2022;5(3):221-230. DOI: https://doi.org/10.1002/edm2.338Alhakak A, Butt JH, Gerds TA, et al. Glycated haemoglobin levels among 3295 hospitalized COVID‐19 patients, with and without diabetes, and risk of severe infection, admission to an intensive care unit and all‐cause mortality. Diabetes, Obesity and Metabolism. 2022;24(3):499-510. DOI: https://doi.org/10.1111/dom.14604Smati S, Tramunt B, Wargny M, et al. COVID-19 and Diabetes Outcomes: Rationale for and Updates from the CORONADO Study. Current Diabetes Reports. 2022;22(2):53-63. DOI: https://doi.org/10.1007/s11892-022-01452-5Yeh HC, Kraschnewski JL, Kong L, et al. Hospitalization and mortality in patients with COVID-19 with or at risk of type 2 diabetes: data from five health systems in Pennsylvania and Maryland. BMJ Open Diabetes Research and Care. 2022;10(3):e002774. DOI: https://doi.org/10.1136/bmjdrc-2022-002774Dedov II, Mokrysheva NG, Shestakova MV, et al. Glycemia control and choice of antihyperglycemic therapy in patients with type 2 diabetes mellitus and COVID-19: a consensus decision of the board of experts of the Russian association of endocrinologists. Diabetes mellitus. 2022;25(1):27-49. Russian. DOI: https://doi.org/10.14341/DM12873Ho TW, Huang CT, Tsai YJ, et al. Metformin use mitigates the adverse prognostic effect of diabetes mellitus in chronic obstructive pulmonary disease. Respiratory Research. 2019;20(1):69. DOI: https://doi.org/10.1186/s12931-019-1035-9Chen Y, Lv X, Lin S, et al. The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis. Frontiers in Endocrinology. 2022;13(7):646-651. DOI: https://doi.org/10.3389/fendo.2022.895458Nguyen NN, Ho DS, Nguyen HS, et al. Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis. Metabolism. 2022;131(2):155196. DOI: https://doi.org/10.1016/j.metabol.2022.155196Mendy A, Gopal R, Alcorn JF, et al. Reduced mortality from lower respiratory tract disease in adult diabetic patients treated with metformin. Respirology. 2019;24(7):646-651. DOI: https://doi.org/10.1111/resp.13486Shestakova EA, Sklyanik IA. Metformin Therapy from the Onset to the Remission of Type 2 Diabetes Mellitus. Effektivnaya farmakoterapiya. 2022;18(47):28-32. Russian. DOI: https://doi.org/10.33978/2307-3586-2022-18-47-28-32Dapagliflozin in Respiratory Failure in Patients With COVID-19 (DARE-19) [Internet] [cited 2023 Apr 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT04350593Wiviott SD, Raz I, Bonaca MP, et al Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2019;380(4):347-357. DOI: https://doi.org/10.1056/NEJMoa1812389McMurray JJ, Solomon SD, Inzucchi SE, et al. DAPA-HF trial committees and investigators. dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine. 2019;381(21):1995-2008. DOI: https://doi.org/10.1056/NEJMoa1911303Petrillo MG, Bortner CD, Cidlowski JA. Glucocorticoids: Inflammation and Immunity. In: Geer E, editor. The Hypothalamic-Pituitary-Adrenal Axis in Health and Disease. Springer, Cham; 2017. DOI: https://doi.org/10.1007/978-3-319-45950-9_3European Society of Cardiology. Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers [Internet] [cited 2023 Mar 13]. Available from: https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-angАmerican Heart Association. HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19 [Internet] [cited 2023 Mar 13]. Available from: https://professional.heart.org/professional/ScienceNews/UCM_505836_HFSAACCAHA-statement-addresses-concerns-re-using-RAAS-antagonists-in-COVID-19.jsp